Social functioning: should it become an endpoint in trials of antidepressants? (Q36090601)

12 August 2017

1 reference

title

Social functioning: should it become an endpoint in trials of antidepressants? (English)

1 reference

12 August 2017

Per Bech

1

0 references

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

19

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

313-324

1 reference

An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder

12 August 2017

cites work

1 reference

12 December 2020

Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo

1 reference

12 December 2020

Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly

1 reference

12 December 2020

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

12 December 2020

Social functioning and the treatment of depression

1 reference

12 December 2020

Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses

1 reference

12 December 2020

Social Adaptation Self-evaluation Scale (SASS): Psychometric analysis as outcome measure in the treatment of patients with major depression in the remission phase

1 reference

12 December 2020

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database

1 reference

12 December 2020

The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

[Treatment of depressive states with an iminodibenzyl derivative (G 22355)]

1 reference

12 December 2020

The Hamilton depression scale. Evaluation of objectivity using logistic models

1 reference

12 December 2020

Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression

1 reference

12 December 2020

Special issue. Translating functional health and well-being: International Quality of Life Assessment (IQOLA) Project Studies of the SF-36 Health Survey. Issue dedicated to Denis Bucquet

1 reference

12 December 2020

Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

1 reference

12 December 2020

Revising axis V for DSM-IV: a review of measures of social functioning

1 reference

12 December 2020

Treating depressed primary care patients improves their physical, mental, and social functioning

1 reference

12 December 2020

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

1 reference

12 December 2020

Social functioning in depression: a review

1 reference

12 December 2020

Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants.

1 reference

12 December 2020

Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey.

1 reference

12 December 2020

Do noradrenaline and serotonin differentially affect social motivation and behaviour?

1 reference

12 December 2020

Suicide risk in placebo-controlled studies of major depression

1 reference

12 December 2020

1 reference

12 December 2020

Unidimensionality and reliability under Mokken scaling of the Dutch language version of the SF-36.

1 reference

12 December 2020

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

12 December 2020

Guidelines on psychotropic drugs for the EC. Committee for Proprietary Medicinal Products. European Economic Community

1 reference

12 December 2020

Efficacy of venlafaxine in depressive illness in general practice

1 reference

12 December 2020

Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination

1 reference

12 December 2020

An Inventory for Measuring Depression

1 reference

12 December 2020

Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older.

1 reference

12 December 2020

Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants

1 reference

12 December 2020

Assessment of social adjustment by patient self-report

1 reference

12 December 2020

Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.

1 reference

12 December 2020

Difference in serotonergic and noradrenergic regulation of human social behaviours.

1 reference

12 December 2020

Outcome measures of antidepressive therapy.

1 reference

12 December 2020

Beyond the Hamilton depression scores in long-term treatment of manic-melancholic patients: prediction of recurrence of depression by quality of life measurements.

1 reference

12 December 2020

A Double-Blind, Placebo-Controlled Study Comparing the Effects of Sertraline Versus Amitriptyline in the Treatment of Major Depression

1 reference

12 December 2020

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

1 reference

12 December 2020

The Hamilton Depression Rating Scale: has the gold standard become a lead weight?

1 reference

12 December 2020

Sensitivity of the six-item Hamilton Depression Rating Scale

1 reference

12 December 2020

Quantitative rating of depressive states

1 reference

12 December 2020

A SELF-RATING DEPRESSION SCALE

1 reference

12 December 2020

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

1 reference

12 December 2020

Getting what you ask for: on the selectivity of depression rating scales

1 reference

12 December 2020

A critical review of dimension-specific measures of health-related quality of life in cross-cultural research

1 reference

12 December 2020

A comparison of three scales for assessing social functioning in primary care

1 reference

12 December 2020

The impact of antidepressant use on social functioning: reboxetine versus fluoxetine

1 reference

12 December 2020

Assessment of social functioning in depression

1 reference

12 December 2020

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants

1 reference

12 December 2020

Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.

1 reference

12 December 2020

An open-label trial of citalopram for major depression in patients with hepatitis C.

1 reference

12 December 2020

10.2165/00023210-200519040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1020339020

0 references

1 reference